Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $285K | $22.2M | $381M | $87.4M | $0.00 |
| Revenue growth | — | 7700.0% | 1612.9% | -77.1% | -100.0% |
| Operating income | -$82.7M | -$201M | $38.8M | -$315M | -$153M |
| Operating margin | -29013.3% | -905.7% | 10.2% | -360.2% | — |
| Net income | -$87.9M | -$198M | $49.3M | -$302M | -$145M |
| Net margin | -30853.0% | -892.4% | 12.9% | -345.4% | — |
| EPS (diluted) | -$13.35 | -$3.39 | $0.70 | -$4.43 | -$1.53 |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Operating cash flow | -$74.8M | -$180M | $11.9M | -$168M | -$123M |
| Capital expenditures | $353K | $2.53M | $1.24M | $157K | $138K |
| Free cash flow | -$75.2M | -$182M | $10.7M | -$168M | -$123M |
| Fiscal year | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cash & equivalents | $50.2M | $62.5M | $170M | $77.4M | $227M |
| Total assets | $106M | $391M | $517M | $194M | $333M |
| Total liabilities | $17.4M | $50.8M | $84.0M | $28.9M | $27.4M |
| Shareholders' equity | -$151M | $341M | $433M | $165M | $305M |
| Retained earnings | -$156M | -$354M | -$305M | -$607M | -$751M |
| Shares (wtd avg diluted) | 6.59M | 58.5M | 70.0M | 68.1M | 94.6M |
Every figure is extracted from Amylyx Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.